SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
We identified and developed a platform technology with prolonged half-life that can target IL-12 and other immune modulators to the TME. Safety and efficacy are being studied using SON-1010 as monotherapy and in combination with checkpoint blockade strategies.
Authors
- Rich Brody
- Stephen J. McAndrew
- Rukiye-Nazan Eraslan
- Susan Dexter
- John K. Cini
- Rebecca J. Boohaker (ORCID: https://orcid.org/0000-0003-3387-1876)
- Suzanne E. Lapi (ORCID: https://orcid.org/0000-0003-0090-0191)
- Richard T. Kenney (ORCID: https://orcid.org/0009-0008-6720-3298)
- Pankaj Mohan
- D. J. Rezac
Institutions
- Southern Research Institute (US)
- University of Alabama at Birmingham (US)
- Centennial Medical Group (US)
- Integrated BioTherapeutics (United States) (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-04
- DOI
- https://doi.org/10.3389/fimmu.2024.1493257
- Citations
- 4
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 1.62